… , but failed in clinical transformation [19,20], which is largely related to the animal model …
shown to have a neuroprotective effect on ischemic stroke in stroke animals and clinical trials. Its …

… The passive avoidance test was used to assess contextual fear learning and memory … not
adult ischemic stroke, can expand over time to other parts of the brain ([5]). Studies have shown …

… stroke risk and therefore a target for neuroprotective … and cardiac populations are vital to
consider if we are to learn from RIC in … pre-clinical studies to beneficial outcomes in clinical trials. …

… improves stroke outcomes in a non-neuroprotective manner. … These neuroprotective drugs
belong to the class of excitatory … As a new treatment modality, many studies are still ongoing …

… We included 53 studies on 21 different therapies. Over the … lasting over 6–24 h is associated
with transitions toward … ranging from reversible synaptic failure to severe cell swelling …

… neuroprotective effects of MSC-secreted EVs in stroke conditions have not been clearly
elucidated to date, which is a prerequisite before clinical trials … -microRNA25 treatment failed to …

… Perhaps we can learn from the experience with cholesteryl ester transfer protein inhibitors, …
, a long litany of trials in acute stroke tested so called neuroprotectants. They all failed. Many …

… neuroprotective effects in animal stroke models but inconclusive results in case series and
randomized clinical trials… clinical trials with theophylline treatment in stroke patients also failed …

… rIPerC may have immediate neuroprotective effects. An important … One randomized controlled
trial included 68 patients with stroke … models have failed in clinical translation. For clinical …

… The relative affinity of the new NAE toward cannabinoid … animals and trials, a ratio between
foot-faults and total steps … per NAE treatment group and n = 10 for the stroke + vehicle (…